Results
|
41.
|
|
|
42.
|
|
|
43.
|
|
|
44.
|
|
|
45.
|
|
|
46.
|
|
|
47.
|
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. [electronic resource] by
- Ratner, E S
- Keane, F K
- Lindner, R
- Tassi, R A
- Paranjape, T
- Glasgow, M
- Nallur, S
- Deng, Y
- Lu, L
- Steele, L
- Sand, S
- Muller, R-U
- Bignotti, E
- Bellone, S
- Boeke, M
- Yao, X
- Pecorelli, S
- Ravaggi, A
- Katsaros, D
- Zelterman, D
- Cristea, M C
- Yu, H
- Rutherford, T J
- Weitzel, J N
- Neuhausen, S L
- Schwartz, P E
- Slack, F J
- Santin, A D
- Weidhaas, J B
Producer: 20130124
In:
Oncogene vol. 31
Availability: No items available.
|